help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
The Oncologist, Vol. 7, No. 5, 389–389, October 2002
© 2002 AlphaMed Press

EDITORS' NOTE

For the oncologist from The Oncologist

In just seven years, The Oncologist has become one of the most important physician-reviewed providers of relevant cancer medicine information. In fact, The Oncologist has become one of the world’s most widely read cancer journals with more than 19,000 readers. Even more astounding are the more than 100,000 readers who monthly visit The Oncologist Online (www.TheOncologist.com) and the more than 30,000 physicians and other health care givers who monthly visit The Oncologist Online Continuing Medical Education (CME.TheOncologist.com).

The prominence of The Oncologist is, of course, the result of many factors, among them the mission to bring relevant information on the multimodality practice of oncology to practitioners who are community based. Papers are, therefore, carefully selected and edited to provide you, our readers, with perspectives that are authoritative and relevant. The selection of these papers, in fact, the entire tone and tempo of the Journal are set and carefully maintained by our Editorial Board. As Editors, we are pleased to welcome the following new members to The Oncologist’s Editorial Board: Alison Freifeld, University of Nebraska Medical Center; John Hainsworth, Sarah Cannon Cancer Center; Judy E. Lundgren, President, Oncology Nursing Society; Steve Piantadosi, Johns Hopkins Oncology Center; Michael Seiden, Massachusetts General Hospital; Paula Trahan Rieger, Past President of the Oncology Nursing Society; Wyndham Wilson, National Cancer Institute.

We gratefully acknowledge those who have concluded their tour of duty on the editorial board: Harry G.G.M. Bartelink, The Netherlands Cancer Institute; Gianni Bonadonna, Istituto Nazionale Tumori; Neil Clendeninn, Drug Development Consultant; David Khayat, Salpetriere Hospital; John F. Smyth, University of Edinburgh.

This year we significantly increased the utility and education of the Journal’s Website by launching The Oncologist CME Online. We are proud to be the first and only journal whose online CME is approved by the National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES). Provided as a free service to all registered users, The Oncologist CME Online covers all aspects of oncology medicine, including courses in Risk Management, important in quality practice and patient care, and very often difficult credits to obtain in the busy clinical setting. Each issue and Journal supplement contains articles providing 4 to 6 hours of new AMA/PRA category 1 credit. We continually welcome feedback from our readers on ways to better meet our readers’ educational needs.

Always striving to report on current controversies in a fair and balanced fashion, we continue to seek what is new and important, recruiting key opinion leaders to author manuscripts for peer-reviewed publication consideration. Keeping the Journal on course, not allowing it to stray from the mission upon which we originally embarked, we have also embarked upon an ambitious identification of key topics that warrant coverage in greater depth. The first five of these freestanding Journal supplements have recently been published to widespread acclaim. They are:

Novel Approaches to the Treatment of Advanced Hematologic Malignancies
The Oncologist 2002;7 (suppl 1):1S-49S.
Schwartz Center Rounds: Volume 1
The Oncologist 2002;7 (suppl 2):1S-65S.
Novel Molecular Targets for Cancer Therapy
The Oncologist 2002;7 (suppl 3):1S-41S.
ZD1839 (IressaTM): A New Targeted Therapy for Solid Tumors
The Oncologist 2002;7 (suppl 4):1S-39S.
Current Perspectives in the Treatment of Ovarian Cancer: An Update on the Role of Topotecan
The Oncologist 2002;7 (suppl 5):1S-55S.

In addition, the following Supplement is in preparation:

Incorporating Oral Capecitabine into the Treatment of Breast Cancer
The Oncologist 2002;7 (suppl 6)

Our greatest appreciation is reserved for cancer patients and you, our readers. It is, after all, to them and for you that we dedicate ourselves and The Oncologist.

The Editors





This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS